• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于条件效能对研究进行的设计扩展。

Designed extension of studies based on conditional power.

作者信息

Proschan M A, Hunsberger S A

机构信息

Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892, USA.

出版信息

Biometrics. 1995 Dec;51(4):1315-24.

PMID:8589224
Abstract

We propose a flexible method of extending a study based on conditional power. The possibility for extension when the p value at the planned end is small but not statistically significant is built in to the design of the study. The significance of the treatment difference at the planned end is used to determine the number of additional observations needed and the critical value necessary for use after accruing those additional observations. It may therefore be thought of as a two-stage procedure. Even though the observed treatment difference at stage 1 is used to make decisions, the Type I error rate is protected.

摘要

我们提出了一种基于条件功效来扩展研究的灵活方法。在研究设计中纳入了在计划结束时p值较小但无统计学显著性时进行扩展的可能性。利用计划结束时治疗差异的显著性来确定所需的额外观察次数以及积累这些额外观察值后使用的临界值。因此,它可被视为一个两阶段程序。尽管在第一阶段观察到的治疗差异用于做出决策,但I型错误率仍得到了控制。

相似文献

1
Designed extension of studies based on conditional power.基于条件效能对研究进行的设计扩展。
Biometrics. 1995 Dec;51(4):1315-24.
2
A two stage conditional power adaptive design adjusting for treatment by covariate interaction.一种通过协变量交互作用调整治疗的两阶段条件效能自适应设计。
Contemp Clin Trials. 2008 May;29(3):428-38. doi: 10.1016/j.cct.2007.10.003. Epub 2007 Oct 26.
3
Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.基于序贯条件概率比检验和反向随机截尾的临床试验设计。
Biometrics. 1998 Jun;54(2):682-95.
4
Optimal conditional error functions for the control of conditional power.用于控制条件功效的最优条件误差函数。
Biometrics. 2004 Sep;60(3):715-23. doi: 10.1111/j.0006-341X.2004.00221.x.
5
A group-sequential design for clinical trials with treatment selection.一种用于有治疗选择的临床试验的序贯分组设计。
Stat Med. 2008 Dec 20;27(29):6209-27. doi: 10.1002/sim.3436.
6
A review of methods for futility stopping based on conditional power.基于条件功效的无效性终止方法综述。
Stat Med. 2005 Sep 30;24(18):2747-64. doi: 10.1002/sim.2151.
7
Over-ruling a group sequential boundary--a stopping rule versus a guideline.推翻一个成组序贯边界——一种停止规则与一项指南的对比
Stat Med. 2003 Nov 15;22(21):3347-55. doi: 10.1002/sim.1636.
8
The B-value: a tool for monitoring data.B值:一种数据监测工具。
Biometrics. 1988 Jun;44(2):579-85.
9
The reassessment of trial perspectives from interim data--a critical view.基于中期数据对试验前景的重新评估——批判性观点。
Stat Med. 2006 Jan 15;25(1):23-36. doi: 10.1002/sim.2180.
10
Optimization of multistage testing times and critical values in clinical trials.优化临床试验中的多阶段测试时间和临界值。
Biometrics. 1993 Sep;49(3):763-72.

引用本文的文献

1
Improving the Effectiveness of Sample Size Re-Estimation: An Operating Characteristic Focused, Hybrid Frequentist-Bayesian Approach.提高样本量重新估计的有效性:一种以操作特征为重点的混合频率主义-贝叶斯方法。
Stat Med. 2025 Feb 10;44(3-4):e10310. doi: 10.1002/sim.10310.
2
A Preplanned Multi-Stage Platform Trial for Discovering Multiple Superior Treatments With Control of FWER and Power.一项预先计划的多阶段平台试验,用于发现多种具有控制家族性错误率(FWER)和检验功效的优势治疗方法。
Biom J. 2025 Feb;67(1):e70025. doi: 10.1002/bimj.70025.
3
New results on optimal conditional error functions for adaptive two-stage designs.
自适应两阶段设计的最优条件误差函数的新结果。
J Appl Stat. 2024 Apr 17;51(15):3178-3194. doi: 10.1080/02664763.2024.2342424. eCollection 2024.
4
Sample Size Reestimation in Stochastic Curtailment Tests With Time-to-Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters.在非比例风险情况下,利用两个形状参数未知的威布尔分布,对具有事件发生时间结局的随机截尾试验进行样本量重新估计。
Pharm Stat. 2025 Jan-Feb;24(1):e2429. doi: 10.1002/pst.2429. Epub 2024 Aug 18.
5
The impact of heterogeneity on the analysis of platform trials with normally distributed outcomes.平台试验中异质性对正态分布结局分析的影响。
BMC Med Res Methodol. 2024 Jul 30;24(1):163. doi: 10.1186/s12874-024-02293-4.
6
Efficient testing of the biomarker positive and negative subgroups in a biomarker-stratified trial.在生物标志物分层试验中对生物标志物阳性亚组和阴性亚组进行有效的测试。
Biometrics. 2024 Mar 27;80(2). doi: 10.1093/biomtc/ujae056.
7
Extension of a conditional performance score for sample size recalculation rules to the setting of binary endpoints.将条件性能评分扩展到二分类结局的样本量重估规则设定。
BMC Med Res Methodol. 2024 Jan 19;24(1):15. doi: 10.1186/s12874-024-02150-4.
8
Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.使用贝叶斯预测能力进行具有多个共同主要终点的试验的无缝 2/3 期设计。
BMC Med Res Methodol. 2024 Jan 17;24(1):12. doi: 10.1186/s12874-024-02144-2.
9
Guidance on interim analysis methods in clinical trials.临床试验中期分析方法指南。
J Clin Transl Sci. 2023 May 15;7(1):e124. doi: 10.1017/cts.2023.552. eCollection 2023.
10
ANALYSIS OF "LEARN-AS-YOU-GO" (LAGO) STUDIES.“边做边学”(LAGO)研究分析。
Ann Stat. 2021 Apr;49(2):793-819. doi: 10.1214/20-aos1978. Epub 2021 Apr 2.